A 28-year-old woman with mild persistent asthma presents to the pulmonology clinic. She uses her salbutamol inhaler 3–4 times per week for symptom relief. She has no nocturnal symptoms and normal lung function. What is the drug of choice for long-term control in this patient?

Explanation

## Asthma Step Therapy & First-Line Control Agent **Key Point:** Mild persistent asthma (symptoms 3–4 times per week, no nocturnal symptoms) falls into GINA Step 2, and the first-line long-term control agent is **low-dose inhaled corticosteroid (ICS)**. ### Why ICS is First-Line **High-Yield:** ICS are the most effective anti-inflammatory agents for asthma control across all severity levels. They: - Reduce airway inflammation and hyperresponsiveness - Prevent exacerbations and remodelling - Have excellent safety profile at low doses in adults - Are guideline-recommended (GINA, NAEPP, BTS) as first-line monotherapy for persistent asthma ### Comparison of Options | Agent | Role | Limitation | |-------|------|------------| | **Low-dose ICS** | First-line control for mild-persistent | None; gold standard | | LABA monotherapy | Never monotherapy; only with ICS | Risk of asthma-related death if used alone | | LTRA | Alternative/adjunct; weaker efficacy | Less effective than ICS; reserved for ICS-intolerant or mild cases | | Theophylline | Obsolete; poor safety/efficacy ratio | Narrow therapeutic window; drug interactions | **Clinical Pearl:** This patient does not need LABA yet (that is Step 3: low-dose ICS + LABA). She needs ICS monotherapy to prevent progression. **Warning:** ~~LABA monotherapy~~ is absolutely contraindicated in asthma without concurrent ICS due to increased mortality risk. [cite:GINA 2023 Global Strategy for Asthma Management and Prevention]